Cadence Pharmaceuticals (CADX)
Cadence Pharmaceuticals Revenues: 8.004M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CADX Revenues Rankings
| Overall | 11th percentile | 3930 of 4425 |
| Sector | 29th percentile | 333 of 470 in Healthcare |
| Industry | 43rd percentile | 74 of 132 in Biotechnology |
CADX Revenues Range, Past 5 Years
| Minimum | 0.35M | Mar 2011 |
| Maximum | 8.004M | Mar 2012 |
| Average | 4.94M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CADX related companies
CADX News
Market Wrap Video + Additions to Watch List http://stks.co/3sz7 including: $CADX $RGLD $CLD $NG $NEM
about 10 days ago by StockTiger
about 10 days ago by StockTiger
Morning Movers 05/04: (LF) (POWI) (MITK) (SPRD) Higher; (BODY) (INVN) (BONE) (CHEF) Lower
May 04, 11:31AM Street Insider
May 04, 11:31AM Street Insider
Cadence Pharmaceuticals, Inc. (CADX) Misses Q1 EPS by 5c; Guides Q2 Sales Below
May 03, 4:36PM Street Insider
May 03, 4:36PM Street Insider
Listen to $CADX Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3ezI
about 24 days ago by earningscast
about 24 days ago by earningscast
$CADX - 9ema crosses 20ema - closes above 50ema - ENTERED BUY LONG order @ Limit 3.63 - if filled enter SellStop at 3.49
about 30 days ago by exkapie
about 30 days ago by exkapie
$CADX http://stks.co/3AKn Long setup. Bullish Harami pattern. Volume perk.
about 57 days ago by VexTrades
about 57 days ago by VexTrades
$CADX forms bullish "Diamond Bottom" chart pattern. http://stks.co/35Zd
about 62 days ago by RecogniaEvents
about 62 days ago by RecogniaEvents
$CADX is 5.1% up since open on unusual high volume and 7.6% up since close.
about 63 days ago by TradeBot
about 63 days ago by TradeBot
Canaccord Genuity Reiterates a 'Buy' on Cadence Pharma (CADX); Expect Growing Ofirmev Adoption
Mar 13, 8:46AM Street Insider
Mar 13, 8:46AM Street Insider
Listen to $CADX Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2nfu
about 76 days ago by earningscast
about 76 days ago by earningscast
Cadence Pharmaceuticals, Inc. (CADX) Posts Slightly Wide Loss of 28c Share
Mar 12, 4:04PM Street Insider
Mar 12, 4:04PM Street Insider
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 12, 4:00PM PR Newswire
Mar 12, 4:00PM PR Newswire
$CADX Upside Blowoff - 15 Minute Down Reversal - Red bar after 4 green bars
about 81 days ago by TradeIdeasQuant
about 81 days ago by TradeIdeasQuant
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV Injection
Feb 06, 5:04PM Benzinga
Feb 06, 5:04PM Benzinga
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
Feb 06, 5:00PM PR Newswire
Feb 06, 5:00PM PR Newswire
$MSO, $LYV, $CADX, $S, $DYN 8 U.S. stocks under $10 to avoid at all costs http://stks.co/1fqp
about 157 days ago by eyeonequities
about 157 days ago by eyeonequities
Wedbush Cuts Price Target on Cadence Pharma (CADX), Tweaks Estimates on OFIRMEV Vial Sales
Nov 23, 1:27PM Street Insider
Nov 23, 1:27PM Street Insider
$CADX holding well $CALL Good buying last few days after hitting bottom Target 6.23
about 188 days ago by biostock
about 188 days ago by biostock
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CADX | 2.72 | -0.08 | -2.86% | 232.61M |
| CADC | 1.68 | +0.00 | +0.00% | 29.94M |
| CACI | 43.65 | -0.27 | -0.61% | 1.156B |
| CACH | 4.72 | -0.20 | -4.07% | 60.65M |
| CACC | 87.78 | -1.28 | -1.44% | 2.249B |
| CAC | 32.21 | +0.56 | +1.77% | 247.05M |
| CAAS | 3.82 | -0.03 | -0.78% | 107.95M |
| CA | 25.12 | -0.04 | -0.16% | 12.20B |
| C | 26.47 | -0.19 | -0.71% | 77.58B |
| BZQ | 85.43 | -3.42 | -3.85% |
